Cargando…

Low level HIV viremia is more frequent under protease-inhibitor containing firstline therapy than under NNRTI-regimens

INTRODUCTION: An association of persistent low level viremia (LLV) below 500 copies/mL and a higher risk of therapy failure is still point of controversial discussion. Furthermore, it seems that LLV occurs more frequently in patients with protease-inhibitor regimens than in NNRTI- / or integrase-inh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wiesmann, Frank, Braun, Patrick, Knickmann, Mechthild, Knechten, Heribert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P296
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225437/ https://www.ncbi.nlm.nih.gov/pubmed/25397572 http://dx.doi.org/10.7448/IAS.17.4.19828

Ejemplares similares

Optimizing Face-to-face Vs. Telehealth Visits: Decision-making Regarding Medication Changes And Reliance On Data From In-person Visits
por: Valente, Megan, et al.
Publicado: (2022)

Prédiction de la gravité des patients atteints d’une pneumonie à Covid-19 à l’aide du Score NEWS2
por: Fidha, S., et al.
Publicado: (2022)

The Emergence of Resistance Under Firstline INSTI Regimens
por: Xie, Zhiman, et al.
Publicado: (2022)

Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala
por: Laker, Eva, et al.
Publicado: (2014)

Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand
por: Teeranaipong, Phairote, et al.
Publicado: (2014)

Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis
por: Stellbrink, Hans-Juergen, et al.
Publicado: (2014)

Antiretroviral therapy (ART) management of Low-Level Viremia in Taiwan (ALLEVIATE)
por: Cheng, Chien-Yu, et al.
Publicado: (2014)

The impact of nevirapine- versus protease inhibitor-based regimens on virological markers of HIV-1 persistence during seemingly suppressive ART
por: Kiselinova, Maja, et al.
Publicado: (2014)

Gag drug resistance mutations in HIV-1 subtype C patients, failing a protease inhibitor inclusive treatment regimen, with detectable lopinavir levels
por: Kelly Pillay, Sameshnee, et al.
Publicado: (2014)

The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
por: Wiesmann, Frank, et al.
Publicado: (2011)

Less frequent follow-up in routine care than in trials does not impact resistance selection in patients failing DRV/r or ATV/r first line treatment
por: Marcelin, Anne-Genevieve, et al.
Publicado: (2014)

Protease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK
por: El Bouzidi, Kate, et al.
Publicado: (2014)

Who gets single tablet regimens (STR), and why?
por: Tarrier, Laura, et al.
Publicado: (2014)

HIV-1 persistent viremia is frequently followed by episodes of low-level viremia
por: Widera, Marek, et al.
Publicado: (2017)

Depression in HIV-positive women is associated with changes in antiretroviral treatment regimens
por: Philippe Küpper-Tetzel, Claus, et al.
Publicado: (2014)

Frequent co-reactivation of Epstein–Barr virus in patients with cytomegalovirus viremia under immunosuppressive therapy and/or chemotherapy
por: Hatayama, Yuki, et al.
Publicado: (2020)

Patients’ willingness to take separate component antiretroviral therapy regimens for HIV in the Netherlands
por: Engelhard, Esther, et al.
Publicado: (2014)

Treatment outcome in HIV+ patients receiving 3- or 4-drug regimens during PHI
por: Maria Bottani, Giulia, et al.
Publicado: (2014)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA
por: Bianco, Claudia, et al.
Publicado: (2014)

Time to virologic failure for patients taking their first antiretroviral regimen and the subsequent resistance profiles
por: Crouzat, Frederic, et al.
Publicado: (2014)

Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice
por: Costarelli, Silvia, et al.
Publicado: (2014)

Inefficacy of Triple Therapy and Comparison of Two Different Bismuth-containing Quadruple Regimens as a Firstline Treatment Option for Helicobacter pylori
por: Kekilli, Murat, et al.
Publicado: (2016)

Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment
por: Sweet, Donna, et al.
Publicado: (2014)

Nephrolithiasis and renal failure among patients exposed to atazanavir, other PIs and PI-free regimens
por: Nkhoma, Ella, et al.
Publicado: (2014)

Early changes in coagulation but not inflammatory biomarkers under intermittent ART: the randomized ANRS 106 WINDOW trial
por: Gallien, Sébastien, et al.
Publicado: (2014)

Should the dose of tenofovir be reduced to 200–250 mg/day, when combined with protease inhibitors?
por: Hill, Andrew, et al.
Publicado: (2014)

Long-term effect of a four-drugs induction regimen for patients with high baseline viral load
por: Maggiolo, Franco, et al.
Publicado: (2014)

Morbidity and mortality in HIV-exposed under-five children in a rural Malawi setting: a cohort study
por: Divala, Oscar, et al.
Publicado: (2014)

Effect of hyperbilirubinaemia on neurocognitive, renal, bone and cardiovascular markers in HIV infection treated with boosted protease inhibitors
por: Barber, Tristan J, et al.
Publicado: (2014)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

Tolerability is more important than simplicity for treatment durability
por: Trottier, Benoit, et al.
Publicado: (2014)

Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicity
por: Patterson, Patricia, et al.
Publicado: (2014)

Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor
por: Fisher, Martin, et al.
Publicado: (2014)

Efficacy and safety of rilpivirine-based regimens in treatment-experienced HIV-1 infected patients: a prospective cohort study
por: Gazaignes, Sandrine, et al.
Publicado: (2014)

Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens
por: Giacomelli, Andrea, et al.
Publicado: (2014)

Efficacy and safety of etravirine-containing regimens in a large cohort of HIV/HCV coinfected patients according to liver fibrosis
por: Luis Casado, Jose, et al.
Publicado: (2014)

Safety analysis of raltegravir/truvada regimen in HIV/HCV co-infected patients without switchback after HCV treatment
por: Ehret, Robert, et al.
Publicado: (2014)

Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors
por: Wiesmann, F., et al.
Publicado: (2014)

Impact of NRTI backbone on renal, bone and cardiovascular markers in HIV-infected individuals receiving a boosted protease inhibitor
por: Barber, Tristan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_op91mprdjf1h657f8p9ql8lopj